• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

    2022-06-07 10:50:12MengLiWuFengLiangLiuJingSunXinLiJianRuQinQiHongYanXiaJinXinWenChenYongTangZhengJinCunZhaoJianHuaWang
    Zoological Research 2022年3期

    Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao,*, Jian-Hua Wang,,5,*

    1 College of Life Science, Henan Normal University, Xinxiang, Henan 453007, China

    2 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China

    3 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology,Chinese Academy of Sciences, Kunming, Yunnan 650223, China

    4 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China

    5 University of Chinese Academy of Sciences, Beijing 100049, China

    ABSTRACT COVID-19 is an immune-mediated inflammatory disease caused by SARS-CoV-2 infection, the combination of anti-inflammatory and antiviral therapy is predicted to provide clinical benefits.We recently demonstrated that mast cells (MCs) are an essential mediator of SARS-CoV-2-initiated hyperinflammation.We also showed that spike protein-induced MC degranulation initiates alveolar epithelial inflammation for barrier disruption and suggested an off-label use of antihistamines as MC stabilizers to block degranulation and consequently suppress inflammation and prevent lung injury.In this study, we emphasized the essential role of MCs in SARS-CoV-2-induced lung lesions in vivo, and demonstrated the benefits of co-administration of antihistamines and antiviral drug remdesivir in SARS-CoV-2-infected mice.Specifically, SARSCoV-2 spike protein-induced MC degranulation resulted in alveolar-capillary injury, while pretreatment of pulmonary microvascular endothelial cells with antihistamines prevented adhesion junction disruption; predictably, the combination of antiviral drug remdesivir with the antihistamine loratadine, a histamine receptor 1 (HR1) antagonist, dampened viral replication and inflammation, thereby greatly reducing lung injury.Our findings emphasize the crucial role of MCs in SARS-CoV-2-induced inflammation and lung injury and provide a feasible combination antiviral and anti-inflammatory therapy for COVID-19 treatment.

    Keywords: SARS-CoV-2; Mast cell; Remdesivir;Antihistamine; Combinational therapy

    INTRODUCTION

    Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection.This infection dysregulates the immune system by inducing hyperinflammatory responses, which produce excessive pro-inflammatory mediators that trigger acute lung injury, septic shock, acute respiratory distress syndrome, and multiple organ failure, thus contributing to significant morbidity and mortality (Attiq et al., 2021; Chen et al., 2020; Huang et al., 2021; Qin et al., 2020; Song et al., 2020; Tian et al., 2021;Wang et al., 2020a; Xu et al., 2020).To curtail this disease,the US Food and Drug Administration (FDA) has approved and authorized two mRNA-based vaccines (Pfizer-BioNTech,Moderna) and one recombinant adenovirus-26 vaccine(Janssen, Ad26.COV2.S) for population use, while the World Health Organization (WHO) has approved the BBIBP-CorV and CoronaVac inactivated vaccines, both of which were developed in China.Globally more than 100 candidate vaccines, including 20 inactivated SARS-CoV-2 vaccines, are under development (Marfe et al, 2021).

    Considering the limited durability of protection conferred by existing vaccines and the real-life reduction in vaccine effectiveness due to the emergence of SARS-CoV-2 variants,efficacious pharmacological treatment for COVID-19 is still urgently needed.Several drugs repurposed from viral disease treatments have been tested against COVID-19, including remdesivir, favipiravir, and lopinavir/ritonavir, which interfere with the function of SARS-CoV-2 RNA-dependent RNA-polymerases (RdRp) (Biswas et al, 2021).The ribonucleoside analogue molnupiravir (EIDD-2 801, MK-4 482), developed by Merck and Ridgeback, has been approved in the UK for the oral treatment of COVID-19 (Mahase, 2021a;c).Paxlovid (PF-07311332 and ritonavir), another oral-administration candidate developed by Pfizer, is reported to reduce the risk of hospitalization or death by 89% compared to placebo in nonhospitalized high-risk adults with COVID-19 (Mahase, 2021b).Furthermore, the Janus kinase (JAK) 1/2 inhibitor baricitinib has been approved for use in Japan (23 April 2021) (Mouffak et al, 2021) and several monoclonal antibodies (mAbs) are under development for COVID-19 treatment and/or prophylaxis (Mouffak et al, 2021).

    Remdesivir is a nucleotide analogue that can efficiently inhibit viral RdRp, with well-established activity against various flaviviruses (Konkolova et al, 2020).Remdesivir shows efficient repression of SARS-CoV-2 replication in cellular and mouse models (Pruijssers et al, 2020), and shortens recovery time in adult patients following early administration (Beigel et al, 2020; De Clercq, 2021; Rochwerg et al, 2020; Wang et al,2020b, 2020c).Thus, remdesivir (Veklury) has been approved by the US FDA for the treatment of COVID-19 in adults and children older than 12 years (Rubin et al, 2020).

    Many COVID-19 patients manifest symptoms associated with inflammation (Attiq et al, 2021; Daher, 2021), and the combination of anti-inflammatory and antiviral therapy seems to be beneficial (De Clercq, 2021; Mouffak et al, 2021).The combination of remdesivir with corticosteroids(dexamethasone) reduces both viral load and inflammation in hamster models of SARS-CoV-2 infection (Ye et al, 2021),and reduces the 30-day mortality rate from 19.7% to 12.6% in severe COVID-19 patients (Benfield et al, 2021).Remdesivir combined with the JAK 1/2 inhibitor baricitinib is superior to remdesivir alone in shortening recovery time and accelerating clinical improvement, especially in patients receiving high-flow oxygen or noninvasive ventilation, with fewer serious adverse events (Kalil et al, 2021).

    Mast cells (MCs) are tissue-resident cells strategically placed throughout the host-environment interface.In addition to being the main effector cells in allergic response, MCs also play regulatory roles in various pathophysiological processes(Komi et al., 2020; Lam et al., 2021).Postmortem lung biopsies of COVID-19 patients show a massive increase in the density of perivascular and septal MCs (Da Silva Motta Junior et al., 2020; Dos Santos Miggiolaro et al., 2020).SARS-CoV-2 infection is reported to trigger MC infiltration into the pulmonary parenchyma of African green monkeys (Malone et al, 2021).We also recently demonstrated that SARS-CoV-2 triggers rapid degranulation of MCs and initiates alveolar epithelial inflammation and subsequent lung injury in mice (Wu et al, 2021).These studies suggest that MCs may play a critical role in the pathogenesis of SARS-CoV-2 and may be a novel therapeutic cell target for the treatment of COVID-19(Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).Indeed, we previously found that administration of clinically approved MC stabilizers (i.e., antihistamines ebastine and loratadine) dampens SARS-CoV-2-induced production of proinflammatory factors and prevents lung injury in mice (Wu et al, 2021).In this study, we revealed the essential role of MCs in SARS-CoV-2-induced lung injury.Notably, we investigated the potential benefits of suppressing viral replication and alleviating hyperinflammation by co-administration of antihistamines and remdesivir in a mouse model of SARSCoV-2 infection.

    MATERIALS AND METHODS

    Ethics statement

    All animal experiments were approved by the Institutional Animal Care and Use Committee of the Guangzhou Institutes of Biomedicine, Chinese Academy of Sciences (Approval No.N2021016).All SARS-CoV-2 animal model experiments and protocols were discussed extensively with biosafety officers and facility managers.All animal and viral experiments were conducted within an animal biosafety level 3 (ABSL-3) facility.

    Cells

    Human MCs (LAD2) were cultured in RPMI 1640 medium(Gibco, USA) containing 10% fetal bovine serum (FBS)(Gibco, USA) with 100 U/mL penicillin and 100 μg/mL streptomycin.For degranulation, the LAD2 cells were grown in StemPro-34 medium (Gibco, USA) supplemented with 100 μg/mL stem cell factor (Novoprotein, China), 10 μg/mL interleukin-6 (IL-6) (Novoprotein, China), nutrient supplement(NS) (Gibco, USA), 100 U/mL penicillin (Invitrogen, USA),100 μg/mL of streptomycin (Invitrogen, USA), and 2 mmol/L L-glutamine (Gibco, USA).Human lung microvascularendothelial cells (HULEC-5a) were cultured in MCDB131 medium (Gibco, USA) containing 10 ng/mL epidermal growth factor (EGF) (R&D, USA), 1 μg/mL hydrocortisone (Apexbio,China), 10 mmol/L L-glutamine (Gibco, USA), 10% FBS(Gibco, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin.

    Mast cell degranulation

    The LAD2 cells (3×105) were exposed to recombinant receptor-binding domain (RBD) derived from wild-type SARSCoV-2 (GenScript, Z03483, China) or the 501Y.V2 variant(GenScript, Z03531, China) for indicated times.The cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, USA) at room temperature (RT) for 30 min, then washed three times with phosphate-buffered saline (PBS), and incubated with antiavidin-FITC (500 ng/mL, Invitrogen, A821, USA) diluted in permeabilized buffer (1% FBS and 0.2% Triton X-100 in PBS)for 1 h at 4 °C.After washing, cells were detected with flow cytometry (BD Accuri C6, USA) and analyzed with FlowJo v7.6.1 (USA).Histamine in the LAD2 cell culture supernatants was quantified with an enzyme-linked immunosorbent assay(ELISA) kit according to the manufacturer’s instructions(Sangon Biotech, D751012, China).Compound 48/80(C48/80) (4 μg/mL) (Sigma, C2313, USA), which can stimulate MC degranulation, was used as the control.All experiments were performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Mouse infection

    Specific pathogen-free 6-week-old female wild-type BALB/c mice were infected intranasally with the 501Y.V2 SARS-CoV-2 variant (B.1.351, GISAID: EPI_ISL_2423556) at a 50% cell culture infective dose (CCID50) of 7.1×104.The 501Y.V2 strain was provided by Guangzhou Medical University,Guangdong, China.Loratadine (Lor.) (10 mg/kg) (Sigma-Aldrich, USA) was administered intraperitoneally (i.p.) 1 day before infection and Lor.treatment was continued each day over the course of infection; remdesivir (25 mg/kg) was administered (i.p.) at the time of infection and used once daily until euthanasia.Five mice in each group and three mice in control group.The lungs were collected at 3 days postinfection (dpi) for pathological, virological, and immunological analyses.Experiments were performed in the ABSL-3 facility at the First Affiliated Hospital of Guangzhou Medical University.

    Pathology

    The lungs of mice were harvested and fixed in zinc formalin.For routine histology, tissue sections (~4 μm each) were stained with hematoxylin and eosin (H&E) or toluidine blue.In brief, the tissue sections were stained with 1% toluidine blue(Sigma-Aldrich, USA) for 1 h at RT, then washed in distilled water three times, anhydrous ethanol two times, and covered with a coverslip.Pathological score was assessed according to the degree of lung tissue lesions, including alveolar septal thickening, hemorrhage, inflammatory cell infiltration, and consolidation.Semi-quantitative assessment was determined as follows: 0: No alveolar septal thickening; 1: Very mild alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, and inflammatory cell infiltration<10%; 2: Mild alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, and inflammatory cell infiltration 10%-25%; 3: Moderate alveolar septal thickening,with area of alveolar septal thickening, hemorrhage,inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate 25%-50%; 4: Marked alveolar septal thickening, with area of alveolar septal thickening,hemorrhage, inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate 50%-75%; 5: Very marked alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate >75%.

    For immunofluorescence, frozen lung sections were blocked with 5% bovine serum albumin (BSA) in PBS at RT for 1 h,incubated with anti-VE-cadherin primary antibodies (Abcam,ab205336, UK) for 2 h at RT, then incubated with Alexa Flour 488-labeled goat anti-rabbit IgG (Invitrogen, A11034, USA) for 1 h at RT.The sections were further incubated with DAPI(Beyotime, China) and analyzed using a Pannoramic MIDI slice scanning apparatus (3DHISTECH, USA).The fixed tissue sections were stained at the Pathology Center of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Flow cytometry and fluorescence microscopy

    To detect VE-cadherin expression using flow cytometry,HULEC-5a cells (1×105) were treated with RBD proteins(2 μg/mL) derived from wild-type SARS-CoV-2 (GenScript,Z03483, China) and co-cultured with LAD2 cells (1×105) in the presence or absence of RBD proteins (2 μg/mL) or stimulated with RBD-treated LAD2 cell culture supernatants (300 μL) for 48 h at 37 °C.Medium treatment was used as the control.In other groups (3 repeats), Lor.(2.5 μg/mL, Selleck,China),ebastine (Eba., 1.5 μg/mL, Selleck, China), or ketotifen fumarate (Ket., 4 μg/mL, Yuanye Biology, S46226, China) was used to pretreat HULEC-5a cells for 2 h before stimulation.The cells were harvested and blocked with 5% BSA for 1 h at RT, incubated with anti-VE-cadherin antibodies (Cell Signaling Technology, D87F2, USA) for 2 h at RT, washed with FACS buffer, incubated with Alexa Flour 488-labeled goat anti-rabbit(Invitrogen, A11034, USA) for 30 min at RT, then analyzed using flow cytometry.The HULEC-5a cells were also seeded on a coverslip to form a monolayer to observe VE-cadherin fluorescence using an Olympus CKX53 fluorescence microscope (Japan).

    To detect IL-6 expression at the protein level, HULEC-5a cells (3×105) were treated with LAD2 culture supernatant(250 μL) for 24 h at 37 °C, then harvested, mixed with a leukocyte activation cocktail containing BD GolgiPlug (BD,550583, USA), and cultured for 6 h at 37 °C.Following activation, cells were washed with FACS buffer.The BD Cytofix/Cytoperm solution (BD, 554722, USA) was used for the simultaneous fixation and permeabilization of cells for 20 min at 4 °C before intracellular cytokine staining.Rat antihuman IL-6-PE (BD, MQ2-6A3, USA) was added, and the cells were further incubated at 4 °C overnight.After washing,the cells were resuspended in FACS buffer, then analyzed using flow cytometry (BD Accuri C6, USA) and FlowJo v7.6.1(USA).In other groups (3 repeats), Lor.(2.5 μg/mL, Selleck,China), Eba.(1.5 μg/mL, Selleck, China), or Ket.(4 μg/mL,Yuanye Biology, S46226, China) was used to pretreat HULEC-5a cells for 2 h at 37 °C before stimulation with the LAD2 culture supernatant.All experiments were performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Real-time polymerase chain reaction (RT-PCR)

    Total RNA from cells/tissues was extracted using TRIzol Reagent (Invitrogen, USA), then reverse transcribed into cDNA using a synthesis kit (TOYOBO, FSQ-301, Japan)according to the manufacturer’s instructions.RT-PCR was carried out using SYBR qPCR Mix (GeneSTAR, A33-101,China) with the following thermal cycling conditions: initial denaturation at 95 °C for 2 min, amplification with 40 cycles of denaturation at 95 °C for 15 s, primer annealing at 60 °C for 15 s, and extension at 72 °C for 30 s.The data were analyzed by SYBR green-based semi-quantification and normalized withGAPDH.RT-PCR was performed on the Bio-Rad CFX96 Real-Time PCR system (USA).Mouse-extracted RNA was used to measure copies of the SARS-CoV-2 nucleocapsid gene using a THUNDERBIRD Probe One-step qRT-PCR Kit(TOYOBO, Japan).The standard samples were provided by Dr.Ling Chen (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China).The primers and probes used for RT-PCR are listed in Supplementary Table S1.Mouse tissue RNA was isolated in the ABSL-3 facility at the First Affiliated Hospital of Guangzhou Medical University, and RT-PCR was performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    RNA sequencing (RNA-seq) and data analysis

    The HULEC-5a cells were cultured with RBD-treated LAD2 cell culture supernatants for 24 h at 37 °C.Total RNA was extracted using TRIzol (Invitrogen,USA) according to the manufacturer’s protocols, and ribosomal RNA was removed using a QIAseq FastSelect-rRNA HMR Kit (Qiagen,Germany).Fragmented RNA (average length ~200 bp) was subjected to first- and second-strand cDNA synthesis,followed by adaptor ligation and enrichment under a low cycle according to the instructions provided with the NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs,USA).The purified library products were evaluated using Agilent 2200 TapeStation and Qubit v2.0 (Life Technologies,USA).The libraries were paired-end sequenced (PE150,sequencing reads 150 bp) at Genewiz (China) using the Illumina HiSeq 3000 platform.

    Raw RNA-seq reads were filtered using Trimmomatic v0.36.The filtered reads were mapped to the human (hg38)reference genome using HISAT v2.1 and corresponding gene annotations (GRCh38.p13) with default settings.Total counts per mapped gene were determined using the FeatureCounts function in the SubReads package v1.5.3 with default parameters.The counts matrix was then obtained using the feature counts as input for differential gene expression analysis with the Bioconductor package DESeq2 v1.26 in R v4.0.Gene counts with more than five reads in a single sample or more than 50 total reads across all samples were retained for further analysis.The filtered counts matrix was normalized using the DESeq2 method to remove libraryspecific artifacts.Principal component analysis was based on global transcriptome data using the build-in function prcomp in R.Genes with a log2 fold-change>1 or <-1 and adjustedP<0.05 (Benjamini-Hochberg corrected) were considered significant.Transcription factor and functional enrichment analyses were performed using Metascape (Zhou et al, 2019)(https://metascape.org/gp/index.html#/main/step1).Gene set enrichment analysis (GSEA) was conducted using the R package clusterProfiler v3.18.1.

    Statistical analysis

    GraphPad Prism v8.0 was used for statistical analysis.For direct intragroup comparison, student’s unpaired two-tailedttest was performed to analyze significant differences.For comparisons among multiple groups, one-way analysis of variance (ANOVA) was performed.Significance levels were determined at*:P<0.05;**:P<0.01;***:P<0.001.

    RESULTS

    Spike-induced MC degranulation predisposes microvascular endothelial cells to damage

    We previously demonstrated that SARS-CoV-2 spike/RBD protein-induced MC degranulation initiates alveolar epithelial inflammation and barrier disruption in mice (Wu et al, 2021).To investigate whether the presence of MCs or their degranulation induces alveolar-capillary injury, HULEC-5a cells were seeded on a coverslip to form a cell monolayer,then treated with spike/RBD-stimulated LAD2 cell culture supernatant (Deg.Supern.) for 48 h.The adherent junction protein VE-cadherin in the HULEC-5a cells was examined as an indicator of microvascular endothelial barrier integrity(Wang et al, 2020a).Results showed that Deg.Supern.markedly altered VE-cadherin organization in the HULEC-5a cells (Figure 1A).Direct stimulation with spike/RBD for 48 h or co-culture with LAD2 cells did not disrupt VE-cadherin;however, the addition of spike/RBD to the co-culture of LAD2/HULEC-5a cells (LAD2/RBD) altered VE-cadherin organization (Figure 1B).

    Histamine receptor 1 (HR1) antagonists (i.e., Ket., Eba., and Lor.) are routinely used to treat allergies in humans (Slater et al, 1999).In addition to their primary mechanism of antagonizing histamine at HR1, they may also act on other mediators of allergic reactions (Abdelaziz et al, 2000; Slater et al, 1999).Thus, we next investigated whether these antihistamines could provide protection against MC degranulation-induced disruption of adhesion junctions.HULEC-5a cell monolayers were first pretreated with the antihistamines, then co-cultured with LAD2 cells in the presence of the spike/RBD protein or directly treated with the spike/RBD-stimulated LAD2 cell culture supernatant.Results showed that pretreatment with the antihistamines rescued MC degranulation-triggered disruption of VE-cadherin (Figure 1C).

    The MC degranulation-induced disruption of VE-cadherin in the HULEC-5a cells was quantified using flow cytometry.Results showed that treatment with the spike/RBD-stimulated LAD2 cell culture supernatant (Deg.Supern.) (Figure 1D) orco-culture with LAD2 cells in the presence of the spike/RBD protein (LAD2/RBD) (Figure 1E) decreased VE-cadherin expression.However, pretreatment of the HULEC-5a cells with the antihistamines rescued VE-cadherin impairment(Figure 1D, E).

    Figure 1 MC degranulation disrupts VE-cadherin in HULEC-5a cells

    We previously showed that SARS-CoV-2 spike/RBD triggers MCs to release cellular mediators (Wu et al, 2021).Here, the spike/RBD-induced rapid degranulation of MCs was confirmed by assessing the reduction in immunostaining intensity of cytoplasmic avidin particles (Figure 1F), and histamine released in the cell culture supernatants was quantified (Figure 1G).

    Taken together, these results demonstrate that spike/RBD-triggered MC degranulation predisposes microvascular endothelial cells to damage.

    Pretreatment of microvascular endothelial cells with antihistamines abolishes MC degranulation-induced inflammation

    We next performed transcriptome analysis to examine inflammation in microvascular endothelial cells induced by MCdegranulation.The culture supernatants of spike/RBD-treated LAD2 cells were used to treat HULEC-5a cells for 24 h, after which the cell transcriptomes were analyzed using standard protocols.Data from five independent repeats were analyzed.As shown in the volcano plot, a total of 1 641 up-regulated genes and 835 down-regulated genes were identified in the HULEC-5a cells after treatment with the spike/RBD-treated LAD2 cell supernatant (Figure 2A).Gene Ontology (GO)functional enrichment analysis of differentially expressed genes (DEGs) showed obvious up-regulation of gene sets involved in cytokine signaling/production and inflammation regulation (Figure 2B).GSEA linked the up-regulated genes to inflammatory response regulation (Figure 2C).The core DEGs involved in the regulation of inflammation were catalogized,with significant enrichment in pro-inflammatory cytokine/chemokine-encoding genes, particularly S100 calcium binding protein A9 (S100A9), C-X-C motif chemokine ligand 11(CXCL11), C-C motif chemokine ligand 7 (CCL7), CX-C motif chemokine 10 (CXCL10),IL-6, and intercellular cell adhesion molecule-1 (ICAM-1) (Figure 2D).The expression levels of these significantly up-regulated cytokine/chemokineencoding genes were confirmed using qRT-PCR (Figure 2E).Notably, pretreatment of the HULEC-5a cells with Ket., Eba.,or Lor.significantly reduced MC degranulation-induced expression of these pro-inflammatory cytokines/chemokines(Figure 2E).IL-6 expression at the protein level was detected by intracellular immunostaining and flow cytometry, which confirmed the above findings (Figure 2F, G).Taken together,these results indicate that spike/RBD-triggered MC degranulation significantly induces inflammation in human microvascular endothelial cells, and pretreatment of cells with antihistamines abolishes the subsequent induction of inflammatory factors.

    Combination of remdesivir and antihistamine reduces SARS-CoV-2 replication and inflammation and protects lung injury

    We next investigated whether the co-administration of remdesivir and antihistamines can repress SARS-CoV-2 replication and alleviate inflammation.The 501Y.V2 strain of SARS-CoV-2 was used to infect wild-type BALB/c mice (Shuai et al, 2021).The spike/RBD of this variant triggered MC activation for rapid degranulation with dose-dependent effects(Supplementary Figure S1).

    The BALB/c mice were treated with the antihistamine Lor.(10 mg/kg; i.p.) 1 day prior to intranasal infection with the 501Y.V2 variant (7.1×104CCID50), then administered Lor.once daily until the mice were euthanized at 3 dpi.Remdesivir(25 mg/kg) was administered (i.p.) at the point of infection and used once daily until euthanasia (Figure 3A).

    Compared with the infection group, the administration of Lor.and/or remdesivir did not further accelerate weight loss in mice (Figure 3B).As expected, the administration of remdesivir resulted in a 10-fold decrease in the SARS-CoV-2 viral load in the lung (Figure 3C).While administration of Lor.alone did not markedly suppress viral load (Figure 3C) (Wu et al, 2021), it significantly reduced the production of proinflammatory cytokines/chemokines, such asIL-6, tumor necrosis factor α (TNF-α), C-C motif chemokine ligand 5(CCL5),CXCL11, C-C motif chemokine ligand 20 (CCL20),andICAM-1(Figure 3D).Interestingly, while remdesivir showed incomplete inhibition of pro-inflammatory factor production, co-administration of Lor.and remdesivir greatly reduced pro-inflammatory factors to similar basal levels detected in the mock-infected controls (Figure 3D).

    Frozen lung sections were immunostained for VE-cadherin to visualize pulmonary microvascular integrity (Wang et al,2020a).SARS-CoV-2 infection disrupted the integrity,remdesivir alone maintained integrity to some extent, but completely preserved integrity when combined with Lor.(Figure 3E).

    Mouse lung pathology was analyzed by H&E staining.Lung lesions, including alveolar septal thickening, inflammatory cell infiltration, mucosa desquamation, hyperemia, and hemorrhage, were observed in the SARS-CoV-2-infected mice(Figure 4A).Remdesivir administration reduced lung lesions,although damage still occurred.Notably, administration of Lor.or remdesivir/Lor.in combination greatly reduced lung lesions(Figure 4A).Pathological scores were assessed according to the degree of lung lesions in the tissue sections (Figure 4B).MCs and degranulation were indicated by metachromatic labeling with toluidine blue (Wu et al, 2021).SARS-CoV-2-induced peribronchial accumulation of MCs was observed and granule release was detected in the alveolar space(Figure 5B).Administration with remdesivir alone did not reduce MC accumulation or degranulation (Figure 5B).However, as observed previously (Wu et al, 2021), no MC accumulation or degranulation was observed in the Lor.or combined remdesivir/Lor.groups (Figure 5C-E).

    Figure 2 MC degranulation induces inflammation in human microvascular endothelial cells

    Figure 3 Combined remdesivir and Lor.treatment dampens SARS-CoV-2 replication and inflammation

    Figure 4 Combined remdesivir and Lor.treatment reduces lung lesions in SARS-CoV-2-infected mice

    Figure 5 Administration of Lor.or Lor./remdesivir blocks MC accumulation

    Taken together, these results suggest that co-administration of remdesivir and antihistamines reduces viral replication and inhibits inflammation, thereby preventing lung damage.

    DISCUSSION

    Various therapeutic combinations have been trialed for the treatment of COVID-19, several of which have shown clinical improvement.For example, the addition of minocycline to favipiravir treatment significantly reduces pro-inflammatory cytokines IL-6 and IL-8 in COVID-19 patients (Itoh et al, 2022).The combination of the anti-inflammatory JAK1/2 inhibitor ruxolitinib and anti-C5a complement mAb eculizumab significantly decreases circulating D-dimer levels, reduces pulmonary lesions, and improves respiratory symptoms in severe COVID-19 patients (Giudice et al, 2020).Combined treatment of molnupiravir and favipiravir potentiates antiviral efficacy in SARS-CoV-2-infected hamsters (Abdelnabi et al,2021).Triple antiviral therapy with interferon beta-1b,lopinavir-ritonavir, and ribavirin is superior to lopinavir/ritonavir alone in shortening viral shedding, alleviating disease symptoms, and facilitating recovery in patients with mild to moderate COVID-19 (Hung et al, 2020).In addition, two mAb combinations (casirivimab/imdevimab and bamlanivimab/etesevimab) have been authorized by the US FDA for emergency use to treat non-hospitalized COVID-19 patients with mild to moderate disease but at risk for clinical deterioration (Mouffak et al, 2021).

    As the first antiviral drug formally approved for the treatmentof COVID-19, remdesivir is a priority for developing drug combination.However, treatments used in combination with remdesivir are not limited to anti-inflammatory agents.For example, remdesivir with convalescent plasma shows clinical improvement in severe COVID-19 patients with X-linked agammaglobulinemia (Iaboni et al, 2021).Remdesivir shows synergistic effects at reducing viral replication in cell culture models when used in combination with the antifungal itraconazole (Schloer et al, 2021), antidepressant fluoxetine(Schloer et al, 2021), folate antagonist methotrexate(Stegmann et al, 2021), and Zn-ejector drugs disulfiram or ebselen (Chen et al, 2021).The combination of remdesivir and human soluble ACE2 also displays a strong additive effect on viral replication inhibition (Monteil et al, 2021).

    When remdesivir is used in combination with antiinflammatory agents, one crucial question is the timing for the administration of both components.Early administration of remdesivir shortens the time to clinical improvement in adult COVID-19 patients, but the benefit decreases or disappears when administered at the late phase of infection (Beigel et al,2020; De Clercq, 2021; Rochwerg et al, 2020; Wang et al,2020b), indicating that remdesivir should be administered as early as possible.Here, although remdesivir application at the time of infection significantly reduced pulmonary viral load and lung lesions in mice, it did not completely block the production of pro-inflammatory mediators and thus did not provide full protection against injury.It is possible that drug-inactivated viruses or viral components can still induce rapid inflammationand sequential immune cascades, causing tissue injury (Rauti et al, 2021).Thus, anti-inflammatory agents should also be applied as early as possible before the onset of the inflammatory response.Inadequate blockade of inflammation may account for the lack of clinical benefit found when tocilizumab or corticosteroids are combined with remdesivir(Garibaldi et al, 2021; Rosas et al, 2021).In our study, early combined treatment with the antihistamine loratadine and remdesivir showed complete repression of pro-inflammatory mediator production in infected mice, highlighting the need for early administration of anti-inflammatory agents.

    Growing evidence suggests that MCs play critical roles in the pathogenesis of SARS-CoV-2 (Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).We recently found that SARSCoV-2-induced MC degranulation initiates alveolar epithelial inflammation and causes lung lesions in ACE2-humanized mice (Wu et al, 2021).MCs have also been proposed as novel therapeutic cellular targets for the treatment of COVID-19(Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).Repurposed famotidine, a histamine-2 receptor (HR2)antagonist, significantly improves pulmonary symptoms in COVID-19 patients (Freedberg et al, 2020; Janowitz et al,2020; Malone et al, 2021).Famotidine has also been shown to inhibit Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection (Mukherjee et al, 2021).Administration of famotidine in combination with the HR1 antagonist cetirizine has also been shown to reduce mortality in COVID-19 patients(Hogan Ii et al, 2020; Mather et al, 2020).We previously demonstrated that the antihistamines ebastine and loratadine,as MC stabilizers blocking degranulation, can dampen SARSCoV-2-induced production of pro-inflammatory factors, thereby preventing lung injury in mice (Wu et al, 2021).In this study,these HR1 antagonists were used to pre-block microvascular endothelial cells, resulting in significant repression of inflammatory mediator production in target cells.Importantly,co-administration of loratadine with remdesivir dampened both SARS-CoV-2 replication and inflammation and protected mice from lung injury.

    Taken together, our results emphasize the critical role of MCs in the pathogenesis of SARS-CoV-2 and demonstrate the versatile benefit of antihistamine and remdesivir coadministration in suppressing viral replication and alleviating inflammation in a mouse model of SARS-CoV-2 infection.Our findings provide a feasible approach to combine antiviral and anti-inflammatory agents for COVID-19 treatment.Thus, the clinical benefits warrant further investigation.

    DATA AVAILABILITY

    All raw RNA-seq data used in this study have been deposited at the National Genomics Data Center (BioProjectID PRJCA007111, https://bigd.big.ac.cn/gsa-human/browse/HRA001517), Science Data Bank (Data doi:10.11922/sciencedb.01655, https://www.scidb.cn/s/MBb6r2), and NCBI(BioProjectID PRJNA822440, http://www.ncbi.nlm.nih.gov/bioproject/822440).

    SUPPLEMENTARY DATA

    Supplementary data to this article can be found online.

    COMPETING INTERESTS

    The authors declare that they have no competing interests.

    AUTHORS’ CONTRIBUTIONS

    Conceptualization: J.H.W.; Data Curation and Visualization:M.L.W., F.L.L., J.S., and X.L.Formal Analysis: M.L.W.and J.H.W.; Resources: J.H.W., J.C.Z., J.S., J.R.Q., X.J., Y.T.Z.,and X.W.C.; Software: Q.H.Y.; Writing-Original Draft: M.L.W.and J.H.W.; Writing-Review & Editing: X.J.and J.H.W.; Project Administration: J.H.W., J.C.Z., and Y.T.Z.; Supervision: J.H.W.All authors read and approved the final version of the manuscript.

    ACKNOWLEDGEMENTS

    We thank Prof.Ling Chen for reagents.

    99热这里只有是精品在线观看| 免费少妇av软件| 国产成人免费无遮挡视频| 久久精品国产a三级三级三级| 国产一区二区三区av在线| 久久国产精品男人的天堂亚洲 | 国产v大片淫在线免费观看| 中文精品一卡2卡3卡4更新| 制服丝袜香蕉在线| tube8黄色片| 国产精品熟女久久久久浪| 欧美另类一区| 亚洲欧美精品专区久久| 99re6热这里在线精品视频| 精品亚洲乱码少妇综合久久| 色哟哟·www| 欧美xxⅹ黑人| 亚洲精品中文字幕在线视频 | 国产成人午夜福利电影在线观看| a级毛色黄片| av在线播放精品| 九九久久精品国产亚洲av麻豆| 久久女婷五月综合色啪小说| 久热久热在线精品观看| 日日摸夜夜添夜夜爱| 精品一区二区免费观看| 高清午夜精品一区二区三区| 一级av片app| 一区在线观看完整版| 青春草国产在线视频| 街头女战士在线观看网站| 免费看av在线观看网站| 深夜a级毛片| 国产91av在线免费观看| 久久99热这里只有精品18| 老师上课跳d突然被开到最大视频| 少妇猛男粗大的猛烈进出视频| 97超视频在线观看视频| 免费观看av网站的网址| 婷婷色av中文字幕| 国产一区二区在线观看日韩| 亚洲无线观看免费| 新久久久久国产一级毛片| 国产精品久久久久久久久免| 免费看av在线观看网站| 男人狂女人下面高潮的视频| 亚洲成人一二三区av| 国产精品蜜桃在线观看| 亚洲av欧美aⅴ国产| 精品酒店卫生间| 老师上课跳d突然被开到最大视频| 天堂俺去俺来也www色官网| 亚洲欧美日韩卡通动漫| 国产精品久久久久久精品电影小说 | 免费观看在线日韩| 岛国毛片在线播放| 晚上一个人看的免费电影| 久久久久久久久大av| 国产女主播在线喷水免费视频网站| 啦啦啦啦在线视频资源| 国产免费视频播放在线视频| 久久久久久伊人网av| 又大又黄又爽视频免费| 亚洲最大成人中文| 久久精品国产亚洲av天美| 国产亚洲一区二区精品| 免费观看无遮挡的男女| 成人18禁高潮啪啪吃奶动态图 | 亚洲成人av在线免费| 国产淫片久久久久久久久| 在线观看三级黄色| 黑人高潮一二区| 久久热精品热| 欧美一级a爱片免费观看看| 观看av在线不卡| av在线蜜桃| 人人妻人人爽人人添夜夜欢视频 | 欧美日韩视频高清一区二区三区二| 国产精品一及| 蜜臀久久99精品久久宅男| 亚洲国产日韩一区二区| kizo精华| 熟妇人妻不卡中文字幕| 亚洲欧美一区二区三区国产| 国产免费一区二区三区四区乱码| 国产视频首页在线观看| 少妇人妻久久综合中文| 成人毛片a级毛片在线播放| 国产一区二区三区综合在线观看 | 国产精品国产三级国产专区5o| 美女福利国产在线 | 插阴视频在线观看视频| 久久久精品94久久精品| 亚洲美女视频黄频| 国产亚洲5aaaaa淫片| 男的添女的下面高潮视频| 精品酒店卫生间| 丝袜喷水一区| 丝袜喷水一区| 日韩视频在线欧美| 一级毛片aaaaaa免费看小| 国产av一区二区精品久久 | 春色校园在线视频观看| 天堂8中文在线网| 视频中文字幕在线观看| 色婷婷av一区二区三区视频| 搡女人真爽免费视频火全软件| 99久久精品热视频| av免费在线看不卡| 人妻夜夜爽99麻豆av| kizo精华| 精品一区二区三卡| 嘟嘟电影网在线观看| 中文字幕免费在线视频6| 亚洲av在线观看美女高潮| 中文字幕亚洲精品专区| 亚洲精品国产成人久久av| 搡老乐熟女国产| 少妇的逼好多水| 精品人妻偷拍中文字幕| 午夜福利网站1000一区二区三区| 日本黄色日本黄色录像| 不卡视频在线观看欧美| 国产av一区二区精品久久 | 国产成人午夜福利电影在线观看| 一级爰片在线观看| 亚洲成人一二三区av| 日韩一区二区三区影片| 精品久久久久久久末码| 欧美日韩国产mv在线观看视频 | 80岁老熟妇乱子伦牲交| 亚洲国产精品999| 涩涩av久久男人的天堂| 日韩av免费高清视频| 深夜a级毛片| 成人免费观看视频高清| 亚洲av二区三区四区| 亚洲国产成人一精品久久久| 熟女人妻精品中文字幕| 男男h啪啪无遮挡| 天美传媒精品一区二区| 成人18禁高潮啪啪吃奶动态图 | 亚洲,一卡二卡三卡| 免费av中文字幕在线| 日日撸夜夜添| 欧美亚洲 丝袜 人妻 在线| 91久久精品电影网| 熟女电影av网| 欧美最新免费一区二区三区| 日韩国内少妇激情av| 日韩成人伦理影院| 日韩欧美一区视频在线观看 | 啦啦啦啦在线视频资源| 国产中年淑女户外野战色| 在现免费观看毛片| 国产片特级美女逼逼视频| 国产精品三级大全| 日本wwww免费看| 丰满乱子伦码专区| 色视频在线一区二区三区| 毛片一级片免费看久久久久| 丝袜脚勾引网站| 亚洲精品国产av蜜桃| 欧美97在线视频| 免费黄网站久久成人精品| 国产无遮挡羞羞视频在线观看| 欧美成人午夜免费资源| 亚洲国产毛片av蜜桃av| 国产 精品1| 久久久成人免费电影| 亚洲欧洲国产日韩| 五月伊人婷婷丁香| 97超视频在线观看视频| 国产男女内射视频| 亚洲天堂av无毛| 熟女电影av网| 国产成人精品久久久久久| 女性生殖器流出的白浆| av福利片在线观看| 欧美一级a爱片免费观看看| 亚洲精华国产精华液的使用体验| 亚洲久久久国产精品| 精品少妇黑人巨大在线播放| 国产亚洲av片在线观看秒播厂| 乱码一卡2卡4卡精品| 亚洲三级黄色毛片| 久久国产精品男人的天堂亚洲 | 在线观看免费高清a一片| 亚洲av男天堂| 欧美日韩在线观看h| 亚洲精品aⅴ在线观看| av国产免费在线观看| 国产男女内射视频| 插逼视频在线观看| 国产白丝娇喘喷水9色精品| 成人免费观看视频高清| 成人亚洲精品一区在线观看 | 国产永久视频网站| 国产爱豆传媒在线观看| 2022亚洲国产成人精品| 一区在线观看完整版| www.色视频.com| 亚洲精品色激情综合| 久久99热这里只有精品18| www.色视频.com| 校园人妻丝袜中文字幕| 国产亚洲一区二区精品| 晚上一个人看的免费电影| 精品视频人人做人人爽| 欧美日韩亚洲高清精品| 亚洲欧美日韩东京热| 99热全是精品| 国产黄片视频在线免费观看| 亚洲成人手机| 国产 精品1| 久久精品国产亚洲av天美| 成人午夜精彩视频在线观看| 亚洲在久久综合| 国产一区二区三区综合在线观看 | 五月天丁香电影| 久久99热6这里只有精品| 国产精品久久久久久精品古装| 久久久久久久国产电影| 久久久久性生活片| 亚洲精品一区蜜桃| 久久久久性生活片| 新久久久久国产一级毛片| 欧美 日韩 精品 国产| 精品视频人人做人人爽| 亚洲经典国产精华液单| 免费av不卡在线播放| 大话2 男鬼变身卡| av播播在线观看一区| 只有这里有精品99| 午夜激情久久久久久久| 亚洲国产精品一区三区| av不卡在线播放| 狠狠精品人妻久久久久久综合| 国产欧美日韩精品一区二区| 联通29元200g的流量卡| 久久久久久久久久久丰满| 18+在线观看网站| 亚洲欧美日韩东京热| 午夜福利网站1000一区二区三区| 日本色播在线视频| 麻豆国产97在线/欧美| 亚洲综合精品二区| 成人二区视频| 狠狠精品人妻久久久久久综合| 99久久人妻综合| 免费少妇av软件| 99re6热这里在线精品视频| h日本视频在线播放| 欧美精品一区二区免费开放| 又粗又硬又长又爽又黄的视频| 在线观看三级黄色| 久久久精品94久久精品| 少妇猛男粗大的猛烈进出视频| 麻豆成人午夜福利视频| 嘟嘟电影网在线观看| 在线观看一区二区三区激情| 国产毛片在线视频| 亚洲人成网站高清观看| 久久女婷五月综合色啪小说| 欧美亚洲 丝袜 人妻 在线| 18禁裸乳无遮挡动漫免费视频| 欧美一区二区亚洲| 国产精品国产三级国产av玫瑰| www.色视频.com| av免费观看日本| 精品国产三级普通话版| 一级a做视频免费观看| 亚洲色图综合在线观看| 亚洲精品日本国产第一区| 一级av片app| 欧美一级a爱片免费观看看| 亚洲在久久综合| 一区二区三区精品91| 日韩制服骚丝袜av| 久久久精品94久久精品| 久久午夜福利片| 久久人人爽人人片av| 久久精品国产a三级三级三级| 国产在线男女| 22中文网久久字幕| 久久久久视频综合| 亚洲精品日本国产第一区| h视频一区二区三区| 色5月婷婷丁香| 久久人妻熟女aⅴ| 日本色播在线视频| 少妇的逼好多水| 天天躁日日操中文字幕| 欧美xxxx性猛交bbbb| 亚洲国产精品国产精品| 尾随美女入室| 亚洲精品视频女| 欧美bdsm另类| 免费久久久久久久精品成人欧美视频 | 成人国产av品久久久| 久久精品国产自在天天线| 免费av中文字幕在线| 日韩亚洲欧美综合| 日韩一区二区三区影片| 欧美丝袜亚洲另类| 日韩 亚洲 欧美在线| 久久精品国产亚洲av天美| 久久av网站| 亚洲精品自拍成人| 在线观看国产h片| 欧美精品亚洲一区二区| 97精品久久久久久久久久精品| 免费在线观看成人毛片| 男女无遮挡免费网站观看| 欧美人与善性xxx| 九九在线视频观看精品| 99热国产这里只有精品6| 伦理电影免费视频| 日韩一区二区三区影片| 免费看不卡的av| 欧美亚洲 丝袜 人妻 在线| 我要看日韩黄色一级片| 视频区图区小说| 青春草亚洲视频在线观看| 亚洲欧美日韩另类电影网站 | 大又大粗又爽又黄少妇毛片口| 欧美人与善性xxx| 精品人妻偷拍中文字幕| 久久影院123| 男女下面进入的视频免费午夜| 少妇人妻一区二区三区视频| 一级毛片 在线播放| 国产高清国产精品国产三级 | 色网站视频免费| 精品久久久久久久久亚洲| 黄色怎么调成土黄色| 久久久久久人妻| 亚洲av日韩在线播放| 高清日韩中文字幕在线| 麻豆国产97在线/欧美| 亚洲,一卡二卡三卡| 妹子高潮喷水视频| 成年av动漫网址| 亚洲丝袜综合中文字幕| 亚洲欧美精品自产自拍| 一级毛片 在线播放| 亚洲婷婷狠狠爱综合网| 九九爱精品视频在线观看| 在线精品无人区一区二区三 | 日本欧美国产在线视频| 久久婷婷青草| 久久热精品热| 我的女老师完整版在线观看| 校园人妻丝袜中文字幕| 三级国产精品片| 免费黄频网站在线观看国产| h日本视频在线播放| 亚洲欧美成人综合另类久久久| 久久韩国三级中文字幕| 婷婷色av中文字幕| 看免费成人av毛片| 视频区图区小说| 亚洲欧美清纯卡通| 黄色欧美视频在线观看| 欧美xxⅹ黑人| 成人特级av手机在线观看| 妹子高潮喷水视频| 免费av不卡在线播放| www.色视频.com| 能在线免费看毛片的网站| 极品教师在线视频| 网址你懂的国产日韩在线| 在线观看免费日韩欧美大片 | 日本一二三区视频观看| 亚洲av免费高清在线观看| 久久久久网色| 国产日韩欧美在线精品| 纵有疾风起免费观看全集完整版| 国产亚洲午夜精品一区二区久久| 日韩 亚洲 欧美在线| 中文字幕人妻熟人妻熟丝袜美| av视频免费观看在线观看| 男女边摸边吃奶| 精品一区在线观看国产| 亚洲国产成人一精品久久久| 欧美激情极品国产一区二区三区 | 人妻夜夜爽99麻豆av| 夫妻午夜视频| 乱系列少妇在线播放| 中文字幕久久专区| 人体艺术视频欧美日本| 一本色道久久久久久精品综合| 一级av片app| 国产av码专区亚洲av| 国产一区亚洲一区在线观看| 亚洲四区av| 在线观看一区二区三区激情| 国产爱豆传媒在线观看| 国产高清国产精品国产三级 | 午夜福利网站1000一区二区三区| 偷拍熟女少妇极品色| 内地一区二区视频在线| 免费av不卡在线播放| 99热网站在线观看| 91精品国产国语对白视频| 久久精品国产a三级三级三级| 亚洲国产高清在线一区二区三| 日韩av免费高清视频| 啦啦啦啦在线视频资源| 亚洲中文av在线| www.色视频.com| 亚洲四区av| 日韩视频在线欧美| 91午夜精品亚洲一区二区三区| 久久ye,这里只有精品| 啦啦啦啦在线视频资源| 国产欧美亚洲国产| 99热网站在线观看| 色婷婷久久久亚洲欧美| av视频免费观看在线观看| 中文欧美无线码| 欧美zozozo另类| av黄色大香蕉| 午夜福利网站1000一区二区三区| 成人影院久久| 欧美xxxx性猛交bbbb| 久久精品熟女亚洲av麻豆精品| 久久99精品国语久久久| 最近中文字幕高清免费大全6| 久热久热在线精品观看| 成人亚洲精品一区在线观看 | 夫妻午夜视频| 韩国高清视频一区二区三区| 欧美日本视频| 最黄视频免费看| 好男人视频免费观看在线| 一级爰片在线观看| 这个男人来自地球电影免费观看 | 亚洲自偷自拍三级| 国产乱来视频区| 国产av精品麻豆| 欧美少妇被猛烈插入视频| 99热这里只有精品一区| 亚洲av日韩在线播放| 亚洲aⅴ乱码一区二区在线播放| 狠狠精品人妻久久久久久综合| 欧美区成人在线视频| 亚洲综合色惰| 亚洲国产色片| 不卡视频在线观看欧美| 国产亚洲91精品色在线| 国产无遮挡羞羞视频在线观看| 日本黄色片子视频| 小蜜桃在线观看免费完整版高清| 91aial.com中文字幕在线观看| 国语对白做爰xxxⅹ性视频网站| 一级爰片在线观看| 国产免费一级a男人的天堂| 日韩成人av中文字幕在线观看| 免费黄频网站在线观看国产| 日产精品乱码卡一卡2卡三| 久久99热这里只频精品6学生| 国产 一区 欧美 日韩| 日本免费在线观看一区| 国产精品免费大片| 在线亚洲精品国产二区图片欧美 | 少妇猛男粗大的猛烈进出视频| 一个人免费看片子| 午夜福利在线在线| 精品久久久精品久久久| 中文资源天堂在线| 中国三级夫妇交换| 一本一本综合久久| 午夜免费观看性视频| 亚洲熟女精品中文字幕| 在现免费观看毛片| 国产欧美日韩精品一区二区| av在线蜜桃| 18禁在线播放成人免费| 少妇精品久久久久久久| 蜜臀久久99精品久久宅男| 极品少妇高潮喷水抽搐| 蜜桃在线观看..| 美女国产视频在线观看| 韩国av在线不卡| 亚洲成人av在线免费| 我要看日韩黄色一级片| 国产日韩欧美亚洲二区| 只有这里有精品99| 美女cb高潮喷水在线观看| 亚洲性久久影院| 日韩中文字幕视频在线看片 | 欧美精品人与动牲交sv欧美| 99久久精品国产国产毛片| 国产成人精品福利久久| 激情 狠狠 欧美| 免费黄频网站在线观看国产| 国产精品无大码| 麻豆成人午夜福利视频| 精品酒店卫生间| 欧美另类一区| 国产日韩欧美亚洲二区| 黄片无遮挡物在线观看| 国产在视频线精品| 99国产精品免费福利视频| 国产男人的电影天堂91| 欧美日韩亚洲高清精品| 成人毛片a级毛片在线播放| 国产成人a∨麻豆精品| 国产成人午夜福利电影在线观看| 久久久久久伊人网av| 欧美丝袜亚洲另类| 亚洲第一区二区三区不卡| 色视频在线一区二区三区| 青春草视频在线免费观看| 视频区图区小说| 建设人人有责人人尽责人人享有的 | 国产欧美日韩精品一区二区| 亚洲精品久久久久久婷婷小说| 午夜激情福利司机影院| av在线蜜桃| 97精品久久久久久久久久精品| 永久免费av网站大全| 五月天丁香电影| 精品酒店卫生间| 激情 狠狠 欧美| 欧美97在线视频| 精品国产三级普通话版| 国产精品国产三级国产专区5o| 午夜福利在线观看免费完整高清在| 久久青草综合色| 午夜免费男女啪啪视频观看| 色婷婷av一区二区三区视频| 妹子高潮喷水视频| 久久久久久九九精品二区国产| 一区二区三区免费毛片| 国产成人一区二区在线| 有码 亚洲区| 乱码一卡2卡4卡精品| 少妇被粗大猛烈的视频| 日韩 亚洲 欧美在线| 免费观看av网站的网址| 午夜福利视频精品| 国产成人一区二区在线| av一本久久久久| 一级毛片aaaaaa免费看小| av免费在线看不卡| 99热这里只有精品一区| 日韩不卡一区二区三区视频在线| 国产视频内射| 亚洲av中文av极速乱| 狂野欧美激情性bbbbbb| 日韩欧美 国产精品| 在现免费观看毛片| 欧美区成人在线视频| 大片免费播放器 马上看| 国产在线免费精品| 日本爱情动作片www.在线观看| 亚洲国产精品999| 美女xxoo啪啪120秒动态图| 18+在线观看网站| 一级二级三级毛片免费看| 国产av一区二区精品久久 | 91久久精品国产一区二区成人| 国产伦理片在线播放av一区| 国产亚洲最大av| 80岁老熟妇乱子伦牲交| 亚洲国产欧美人成| 久久婷婷青草| 国产亚洲午夜精品一区二区久久| 亚洲第一av免费看| 各种免费的搞黄视频| 最近最新中文字幕大全电影3| www.色视频.com| 丝瓜视频免费看黄片| 精品国产乱码久久久久久小说| 热re99久久精品国产66热6| 2022亚洲国产成人精品| 欧美xxxx性猛交bbbb| 午夜福利高清视频| 最近2019中文字幕mv第一页| 精品人妻偷拍中文字幕| 精品人妻熟女av久视频| 国产免费一级a男人的天堂| 男人和女人高潮做爰伦理| 成人亚洲欧美一区二区av| 嫩草影院新地址| 国产一区二区三区综合在线观看 | 丰满迷人的少妇在线观看| 久久久欧美国产精品| 亚洲国产欧美人成| 小蜜桃在线观看免费完整版高清| 亚洲国产欧美人成| 国产精品国产av在线观看| 日韩强制内射视频| 欧美日本视频| 青青草视频在线视频观看| 亚洲国产精品999| 国产精品女同一区二区软件| 中文资源天堂在线| 色视频在线一区二区三区| 国产又色又爽无遮挡免| 国国产精品蜜臀av免费| 国产又色又爽无遮挡免| 精品一区在线观看国产| 久久毛片免费看一区二区三区| 精品一区在线观看国产| 中文资源天堂在线| 国产精品女同一区二区软件| 亚洲性久久影院| 精品少妇久久久久久888优播| 亚洲国产日韩一区二区| 美女福利国产在线 | 亚洲精品久久久久久婷婷小说| 成年免费大片在线观看|